Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Case report

PET/CT aids the staging of and radiotherapy planning for early-stage extranodal natural killer/T-cell lymphoma, nasal type: A case series

Authors: Shannon L MacDonald, Liam Mulroy, Derek R Wilke, Steven Burrell

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Extranodal natural killer/T-cell lymphoma (ENKTL), nasal type, is a rare form of non-Hodgkin lymphoma. Treatment of ENKTL primarily relies on radiation; thus, proper delineation of target volumes is critical. Currently, the ideal modalities for delineation of gross tumor volume for ENKTL are unknown. We describe three consecutive cases of localized ENKTL that presented to the Nova Scotia Cancer Centre in Halifax, Nova Scotia. All patients had a planning CT and MRI as well as a planning FDG-PET/CT in the radiotherapy treatment position, wearing immobilization masks. All patients received radiation alone. In two patients, PET/CT changed not only the stage, but also the target volume requiring treatment. The third patient was unable to tolerate an MRI, but was able to undergo PET/CT, which improved the accuracy of the target volume. PET/CT aided the staging of and radiotherapy planning for our patients and appears to be a promising tool in the treatment of ENKTL.
Appendix
Available only for authorised users
Literature
1.
World health organization classification of tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Edited by: Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001, Lyon, France: IARC Press
2.
Liang R: Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol. 2009, 147: 13-21. 10.1111/j.1365-2141.2009.07802.x.CrossRefPubMed
3.
Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-hodgkin's lymphoma classification project. Ann Oncol. 1998, 9: 717-20. 10.1023/A:1008265532487.CrossRefPubMed
4.
Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, Liang R, Kwong YL: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the world health organization classification scheme: a single center experience of 10 years. Ann Oncol. 2005, 16: 206-14. 10.1093/annonc/mdi037.CrossRefPubMed
5.
Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008, 26: 4124-30.CrossRefPubMed
6.
Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS: Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for improving survival of lymphoma study. J Clin Oncol. 2009, 27: 6027-32. 10.1200/JCO.2009.23.8592.CrossRefPubMed
7.
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Ohshima K, Matsuno Y, Terauchi T, Nawano S, Ishikura S, Kagami Y, Hotta T, Oshimi K: Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol. 2009, 27: 5594-600. 10.1200/JCO.2009.23.8295.CrossRefPubMed
8.
Kohrt H, Advani R: Extranodal natural killer/T-cell lymphoma: Current concepts in biology and treatment. Leuk Lymphoma. 2009, 50: 1773-84. 10.3109/10428190903186502.CrossRefPubMed
9.
Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M: FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007, 18: 1685-90. 10.1093/annonc/mdm265.CrossRefPubMed
10.
Wu HB, Wang QS, Wang MF, Li HS, Zhou WL, Ye XH, Wang QY: Utility of 18F-FDG PET/CT for staging NK/T-cell lymphomas. Nucl Med Commun. 2010, 31: 195-200. 10.1097/MNM.0b013e32833310fa.CrossRefPubMed
11.
Khong PL, Pang CB, Liang R, Kwong YL, Au WY: Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol. 2008, 87: 613-21. 10.1007/s00277-008-0494-8.CrossRefPubMed
12.
Torabi M, Aquino SL, Harisinghani MG: Current concepts in lymph node imaging. J Nucl Med. 2004, 45: 1509-18.PubMed
13.
Suh C, Kang YK, Roh JL, Kim MR, Kim JS, Huh J, Lee JH, Jang YJ, Lee BJ: Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med. 2008, 49: 1783-9. 10.2967/jnumed.108.053355.CrossRefPubMed
14.
Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, Saitoh T, Handa H, Endo K, Murakami H: The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007, 110: 652-9. 10.1002/cncr.22807.CrossRefPubMed
15.
Karantanis D, Subramaniam RM, Peller PJ, Lowe VJ, Durski JM, Collins DA, Georgiou E, Ansell SM, Wiseman GA: The value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clin Lymphoma Myeloma. 2008, 8: 94-9. 10.3816/CLM.2008.n.010.CrossRefPubMed
16.
Berk V, Yildiz R, Akdemir UO, Akyurek N, Karabacak NI, Coskun U, Benekli M: Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: Utility of 18F-FDG PET in staging. Clin Nucl Med. 2008, 33: 365-6. 10.1097/RLU.0b013e31816a7a23.CrossRefPubMed
17.
Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL: Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology. 2005, 234: 879-85. 10.1148/radiol.2343030301.CrossRefPubMed
Metadata
Title
PET/CT aids the staging of and radiotherapy planning for early-stage extranodal natural killer/T-cell lymphoma, nasal type: A case series
Authors
Shannon L MacDonald
Liam Mulroy
Derek R Wilke
Steven Burrell
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-182

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue

Research

Virtual 3D tumor marking-exact intraoperative coordinate mapping improve post-operative radiotherapy

Research

Simultaneous in-field boost for patients with 1 to 4 brain metastasis/es treated with volumetric modulated arc therapy: a prospective study on quality-of-life

Research

Risk factors of distant brain failure for patients with newly diagnosed brain metastases treated with stereotactic radiotherapy alone

Research

[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

Research

Carbon ion therapy for advanced sinonasal malignancies: feasibility and acute toxicity

Research

Long-term outcome and patterns of failure in patients with advanced head and neck cancer